Niagen Bioscience, Inc.
NAGEConsumer DefensiveNASDAQPackaged Foods · Last scanned Oct 23, 2026
Scan Results
Daily timeframeHeadquartered within the consumer defensive sector, Niagen Bioscience, Inc. focuses on Packaged Foods services and products. Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. Valued at $200.7M, NAGE is a micro-cap name in its sector. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.
Market Cap
$200.7M
Beta
2.02
P/E (TTM)
13.26
P/E (Fwd)
-42.00
EPS (TTM)
$0.19
EPS (Fwd)
$-0.06
ROE
21.8%
ROA
5.4%
Cash
$66.6M
Total Debt
$2.3M
Free CF
$1.6M
52W Change
-66.0%
Annual Financials
Cash vs Debt
Where NAGE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NAGE finished 30.56% below its 150-day moving average ($3.60) and 39.02% below its 200-day moving average ($4.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NAGE overbought or oversold?
At the October 20, 2026 close, NAGE's RSI(14) was 25.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $66.6M in cash and $2.3M in debt, NAGE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $1.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 21.8% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $72.0M (2022) to $129.4M (2025), reflecting a 80% increase over the period.
Niagen Bioscience, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing NAGE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.